Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Altimmune ( (ALT) ) just unveiled an update.
On April 22, 2026, Altimmune entered into an underwriting agreement with Leerink Partners and Barclays to sell 64,250,000 shares of common stock with accompanying warrants, plus up to 10,750,000 pre-funded warrants, at a public offering price of $3.00 per share or $2.999 per pre-funded warrant. The offering, which closed on April 24, 2026, is expected to generate net proceeds of about $211.2 million, with the securities featuring specified exercise prices, ownership limitations and no planned listing for the warrants.
Altimmune plans to use the proceeds, together with existing cash and investments, to advance clinical development of pemvidutide, including preparation and funding for a global pivotal Phase 3 trial in MASH, to start pre-commercial activities for its lead program, and for general corporate purposes. The capital raise strengthens the company’s funding base for late-stage development, potentially enhancing its competitive standing in the MASH space and providing greater visibility for stakeholders on the financing of its lead asset.
The most recent analyst rating on (ALT) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Altimmune stock, see the ALT Stock Forecast page.
Spark’s Take on ALT Stock
According to Spark, TipRanks’ AI Analyst, ALT is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and cash burn) and bearish/neutral technicals. Offsetting these, the latest earnings call outlined strong clinical progress, regulatory momentum, and funding runway into 2028, which improves the medium-term outlook despite meaningful execution risk as Phase III begins.
To see Spark’s full report on ALT stock, click here.
More about Altimmune
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for metabolic and liver diseases. Its lead program, pemvidutide, targets metabolic dysfunction-associated steatohepatitis (MASH), positioning the company within the competitive market for metabolic and obesity-related therapeutics.
Average Trading Volume: 3,954,574
Technical Sentiment Signal: Sell
Current Market Cap: $375.9M
Learn more about ALT stock on TipRanks’ Stock Analysis page.